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ABSTRACT 
 
Background and Purpose 
Adaptive radiotherapy (ART) can account for the dosimetric impact of 
anatomical change in head and neck cancer patients; however it can be 
resource intensive.  Consequently, it is imperative that patients likely to 
require ART are identified.  The purpose of this study was to find predictive 
factors that identify oropharyngeal squamous cell carcinoma (OPC) and 
nasopharyngeal carcinoma (NPC) patients more likely to need ART. 
 
Materials and Methods 
One hundred and ten patients with OPC or NPC were analysed.  Patient 
demographics and tumour characteristics were compared between patients 
who were replanned and those that were not.  Factors found to be significant 
were included in logistic regression models.  Risk profiles were developed 
from these models.  A dosimetric analysis was performed. 
 
Results 
Nodal disease stage, pre-treatment largest involved node size, diagnosis and 
initial weight (categorised in 2 groups) were identified as significant for 
inclusion in the model.  Two models were found to be significant (p=0.001), 
correctly classifying 98.2% and 96.1% of patients respectively.  Three ART 
risk profiles were developed. 
 
Conclusion 
Predictive factors identifying OPC or NPC patients more likely to require ART 
were reported.  A risk profile approach could facilitate the effective 
implementation of ART into radiotherapy departments through forward 
planning and appropriate resource allocation. 
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Introduction 
Highly conformal, modulated techniques, such as intensity modulated 
radiation therapy (IMRT), helical IMRT (Tomotherapy) and volumetric 
modulated arc therapy (VMAT) are considered the standard radiotherapy 
techniques for the treatment of head and neck squamous cell carcinomas 
(HNSCC).[1-3]  These techniques enable delivery of high radiation doses to 
tumour volumes whilst minimising dose to surrounding structures with 
resultant reduction in toxicities experienced by patients.[4]  However, 
geometric and anatomical changes that can occur over a treatment course 
may limit the benefits associated with these highly conformal techniques and 
should be considered when developing appropriate treatment approaches.[2]  
Anatomical changes can be attributed to a number of factors including 
shrinkage of tumour and nodal volumes, changes in tumour position and 
weight loss.[5, 6]  Various adaptive radiotherapy (ART) techniques have been 
evaluated to assess their effectiveness in addressing this issue however the 
ART process can be resource intensive on departments with replanning 
procedures requiring both additional use of planning equipment and staff 
time.[6, 7]  Consequently, it is imperative that patients who are likely to require 
ART are properly identified.  This will facilitate the effective implementation of 
ART into radiotherapy departments by forward planning, resulting in gains in 
efficiency and appropriate allocation of departmental resources.  ART in this 
context refers to the generation of a new radiotherapy plan based on imaging 
performed during a patient’s treatment course that accounts for anatomical 
changes.   
 
The majority of studies have primarily investigated factors that determine the 
requirement for ART whilst a patient is undergoing treatment.  There is little 
published data on identifying factors that could predict the need for ART prior 
to the commencement of treatment.  As patient selection for ART can be 
subjective, the focus of this study was to identify characteristics that pre-
dispose patients to being more likely to require ART.  Consequently, the 
primary aim of this project was to find predictive factors that identify 
oropharyngeal squamous cell carcinoma (OPC) and nasopharyngeal 
carcinoma (NPC) patients more likely to need ART.  These predictive factors 
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would be used to refine a risk profile approach previously developed.  OPC 
and NPC were chosen as they both commonly present with nodal involvement, 
have a high rate of viral association (Human Papillomavirus (HPV) with OPC 
and Epstein Barr Virus (EBV) with NPC) and respond well to radiotherapy 
treatment. 
 
Materials and Methods 
Patients 
Between October 2013 and December 2014, 110 patients were recruited from 
three tertiary radiotherapy departments in Brisbane, Australia to join a 
prospective cohort study.  This study was approved by the Princess 
Alexandra Hospital and Royal Brisbane and Women’s Hospital Human 
Research Ethics Committee.  Informed consent was obtained.  Eligibility 
criteria included: histologically confirmed NPC or OPC, or metastatic cervical 
nodal disease of unknown primary suspected of arising from either the 
oropharynx or nasopharynx; absence of distant metastatic disease; treatment 
with radical radiotherapy with any IMRT technique including rotational arc or 
helical radiation therapy techniques; a radiation prescription dose of ≥50Gy 
and with or without concurrent chemotherapy.   Patients were excluded: if it 
was unknown whether their disease was virally associated or not; if they had 
undergone definitive resection of the primary tumour, and/or a neck 
dissection; if they were treated with a three-dimensional conformal 
radiotherapy technique and if there was an inability to spare at least one 
parotid gland (i.e. unable to achieve a mean parotid dose of ≤ 26Gy[8] - 
33Gy[9]).  Patient demographics, tumour characteristics (including pre-
treatment size of the dominant node) and treatment details were recorded.  
Nodal size data was collected from each patient’s diagnosis and staging 
information. 
 
Treatment planning 
All patients were positioned supine, immobilised in a thermoplastic mask 
covering the head and shoulder region.  Patients underwent computed 
tomography (CT) simulation procedures according to standard departmental 
protocol and all CT scans were obtained using a helical CT scanner with 3 
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mm slice spacing.  Intravenous (IV) contrast was not used for CT scanning as 
all patients had a positron emission tomography (PET)/CT fused with the 
planning CT for volume definition.  Magnetic resonance imaging (MRI) scans 
were fused as appropriate with the planning CT scan to aid in target 
delineation.  Target volumes were contoured according to the department’s 
standard protocol. 
 
ART management 
Re-CT 
Consented patients were allocated to one of three ART risk profiles primarily 
based on the pre-treatment size of their largest involved node, as previously 
described.[10]  These risk profiles indicated which patients would have a 
second planning computed tomography (CT) scan (re-CT) booked prior to 
treatment commencement at fraction 15.  Patients had a daily, pre-treatment 
cone beam CT (CBCT) or megavoltage CT (MVCT) scan taken.  This scan 
was used during the treatment session to correctly align the isocentre.  Scans 
were reviewed on a weekly basis by one of four Radiation Therapists to 
assess the need for the patient to undergo a re-CT for ART purposes.  For all 
patients, a re-CT was performed if the difference between the planning scan 
and the CBCT was greater than 1 cm at any point of the patient’s external 
contour within the treatment area.  The only circumstance where a re-CT was 
not required was if the patient had seven fractions or less remaining in their 
treatment.   
 
If a difference greater than 1 cm was noted for a patient receiving 
Tomotherapy, the original plan was re-calculated on the MVCT to make an 
initial assessment of the dosimetric impact of the anatomical change.   On 
plan review, if the Radiation Oncologist considered the dosimetric impact to 
be clinically significant, a re-CT was performed.  A flow chart outlining the 
study procedure is demonstrated in Supplementary Figure 1. 
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Supplementary Figure 1 Flow chart outlining study procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment for need of replan 
For all patients that had a re-CT, the original CT and the re-CT were fused 
using rigid registration according to the region of interest specified by the 
Radiation Oncologist to assess the requirement for a new treatment plan 
(replan).  The original plan was translated to the re-CT dataset and calculated 
using the original monitor units (MU).  This method is similar to the hybrid 
Consent of eligible patients 
Allocation to appropriate risk profile (Brown et al 2013) 
 
Low risk 
Dominant pre-treatment 
nodal size ≤ 35mm 
 
Intermediate risk 
Dominant pre-treatment nodal size 
36mm – 45mm 
 
High risk 
Dominant pre-treatment 
nodal size ≥ 46mm 
 All patients have daily volumetric imaging (CBCT or MVCT) 
o Used daily for treatment positioning 
 All images reviewed weekly to determine need for re-CT 
o Difference between planning and treatment external contour >1cm 
o Not applicable if <7 treatment fractions remaining 
Refinement of preliminary risk profiles 
 
No re-CT required 
 
Re-CT required 
Assessment of dosimetric impact 
 Original plan calculated on re-CT 
 Radiation Oncologist review to 
determine need for replan 
o DVH 
o Visual inspection of isodoses 
No replan required 
 
Replan required 
 Must be 
implemented 
in < 5 working 
days 
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technique described by Hansen et al.[6]  The treating Radiation Oncologist 
assessed the image registration and any volumetric deformations or positional 
shifts of target or organ at risk (OAR) structures and reviewed the plan 
through both visual inspection and evaluation of the dose volume histogram 
(DVH).  Nodal gross tumour volumes (GTV-n), serial OAR and parotid glands 
were re-contoured.  The decision to generate a replan was at the discretion of 
the treating Radiation Oncologist.  Factors influencing a Radiation 
Oncologist’s decision to replan included critical OAR, such as the spinal cord 
or optic structures, receiving dose above the accepted tolerance level and 
inadequate target volume coverage. 
 
Doses received by the GTV-n, non-target tissue (NTT), spinal cord, brainstem 
and parotid glands were recorded from both the original plan and the 
delivered dose plan to assess dosimetric impact.  
 
Replan 
If a replan was necessary, target and OAR structures were re-contoured as 
required on the re-CT and a new plan generated.  The aim of the new plan 
was to achieve at least comparable target volume coverage and OAR doses 
to the original plan. 
 
Statistics 
Patients who required a replan were compared with those that did not to 
identify common characteristics among the replan group.  A three-stage 
approach was taken to the statistical analyses.  For the first step, univariate 
and multivariate analyses were used including Chi squared[11] and Mann-
Whitney[12] tests to compare various factors between the two groups.  
Comparison of dosimetric factors was conducted between the original 
treatment plan and the delivered dose using the Wilcoxon matched-pairs 
signed-ranks test.  These tests were used as the data was not normally 
distributed.  Tested factors included gender, age, diagnosis, disease stage, 
viral status, initial weight and initial size of the pre-treatment dominant node.  
A p-value of ≤ 0.05 was considered statistically significant.  For the second 
stage logistic regression was used to model the relationship between the 
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categorical outcome and explanatory variables. The explanatory variables 
used were determined in stage one.  Logistic regression was used as the 
outcome being investigated was binary (i.e. replan).  In the regression 
analyses, the binary response variable was the requirement for a replan and a 
p-value of p ≤ 0.05 was considered to be statistically significant.  Data was 
analysed using the Stata (version 12.1, StataCorp LP, Texas, USA) program.  
For the third stage, classification and regression trees (CART) were used to 
identify interacting relationships between explanatory variables and the 
categorical response variable. Only the identified explanatory variables were 
included in the CART analysis.  CART analysis was performed in RStudio 
version 0.98.110 [13] using the rpart.plot package.[14] 
 
Results 
Patients 
Patient characteristics and treatment details are summarised in Table 1.  The 
cohort comprised of 91.8% males with the primary diagnosis being OPC in 
84.5% and NPC in 11% of patients.  In this cohort, 84.5% of patients had HPV 
or EBV positive disease.  Of the 110 patients, 21 (19.1%) had a re-CT with 5 
(4.5%) resulting in a replan.  Of the 5 patients that were replanned, 3 (60%) 
had a primary diagnosis of NPC.  Patients who underwent replanning only 
had one new plan generated. 
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Table 1 Patient characteristics and treatment details 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic Value (range) 
Sex 
Male 
Female 
 
101 
9 
Median age (years) 59 (28-74) 
Diagnosis 
Oropharynx 
Nasopharynx 
Carcinoma of unknown primary 
 
93 
12 
5 
T classification 
0 
1 
2 
3 
4 
 
7 
17 
37 
23 
26 
N classification 
0 
1 
2 
3 
 
2 
12 
88 
8 
Viral status 
Positive 
Negative 
 
93 
17 
Median smoking history (pack years) 13 (0-100) 
Median initial node size (mm) 30 (6-80) 
Median initial weight (kg) 87.9 (42-150.9) 
Median percentage weight loss 
during treatment (%) 
9.9 (-0.9-28.5) 
Treatment technique 
IMRT 
VMAT 
Tomotherapy 
 
32 
67 
11 
Chemotherapy 
Cisplatin 
Cetuximab 
Other 
Ceased 
 
78 
20 
1 
2 
Median prescribed radiation dose 
(Gy) 
70 (67-70) 
Re-CT 
Oropharynx 
Nasopharynx 
21 
15 
6 
Replan 
Oropharynx 
Nasopharynx 
5 
2 
3 
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Patient characteristics comparison 
The comparison of patient characteristics for those that had a replan and 
those that did not is displayed in Table 2.  Patients who were replanned had 
significantly more advanced nodal disease (p<0.0001), with the majority of 
patients having N2 or higher disease, and larger pre-treatment dominant 
nodal size (p=0.007).  A significant difference was found between diagnoses 
(p=0.001); with the majority of replan patients having NPC, and treatment 
technique (p=0.044) with all replan patients being treated with VMAT or 
Tomotherapy.  All replanned patients had viral positive disease.  
Chemotherapy was not found to be a significant factor in the need for a 
replan.  No other characteristics were found to be statistically significant.  
However, when initial patient weight was split into two categories, those with 
an initial weight less than 100kg and those greater than 100kg, a difference 
approaching significance was noted (p=0.07) with replanned patients having a 
greater initial weight. 
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Table 2 Characteristics comparison between patients that had a replan 
and those that did not 
* indicates statistical significance (p<0.05) 
 
Predictive model 
Factors found to be significant or approaching significance in the multivariate 
analysis were included in the logistic regression model. After initial testing, 
technique was not statistically significant and was removed from the model.  
As having virally disassociated disease predicted failure perfectly, viral status 
Characteristic No replan  
(range) 
n=105 
Replan  
(range) 
n=5 
p-
value 
Sex 
Male 
Female 
 
96 
9 
 
5 
0 
0.494 
Median age (years) 59 (29-74) 52 (28-71) 0.347 
Diagnosis 
Oropharynx 
Nasopharynx 
Carcinoma of unknown 
primary 
 
91 
9 
5 
 
2 
3 
0 
0.001* 
T classification 
0 
1 
2 
3 
4 
 
1 
16 
36 
22 
24 
 
0 
1 
1 
1 
2 
0.863 
N classification 
0 
1 
2 
3 
 
2 
11 
87 
5 
 
0 
1 
1 
3 
<0.001* 
Viral status 
Positive 
Negative 
 
88 
17 
 
5 
0 
0.328 
Median smoking history 
(pack years) 
11 (0-100) 35 (0-50) 
0.362 
Median initial node size (mm) 30 (6-80) 70 (29-70) 0.007* 
Median initial weight (kg) 87.8 (42-150.9) 101.4 (57-130) 0.385 
Median percentage weight 
loss during treatment (%) 
9.6 (-0.9-28.5) 11.6 (8.6-18.9) 
0.116 
Treatment technique 
IMRT 
VMAT 
Tomotherapy 
 
32 
64 
9 
 
0 
3 
2 
0.044* 
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was unable to be included in the model.  Two models were found to best 
predict the need to replan during treatment: 
 
Model 1  
Logit# (replan) = -23.168 + (2.416*N stage) + (5.958*diagnosis) + (0.150*initial 
node size) + (9.562*weight_2 categories) 
Model 2 
Logit# (replan) = -25.218 + (4.031*N stage) + (7.876*diagnosis) + (0.142*initial 
node size) + (10.70*weight_2 categories) 
 
# Logit = log of the odds [log(p/1-p)] 
 
The second model was weighted according to the proportion of patients that 
were replanned in order to increase the sensitivity of the model and place 
greater importance on the requirement to predict patients who will require a 
replan.[15]  The first model was not weighted.  The result of post estimation 
testing of both models is displayed in Table 3. 
 
Table 3 Post estimation results for logistic regression models 
 
 Model 1 Model 2 
p-value 0.001 0.001 
Pseudo R2 0.6153 0.7505 
Sensitivity 60% 100% 
Specificity 100% 92.31% 
Positive predictive value 100% 92.59% 
Negative predictive value 98.11% 100% 
Correctly classified 98.2% 96.1% 
Misclassified 0 8 
 
 
ART risk profiles and CART analysis 
The predictive models were used to determine threshold values for inclusion 
in ART risk profiles that could be implemented clinically.  High risk was 
classed as having a greater than 80% probability for requiring a replan and 
intermediate risk, greater than 60% probability for requiring a replan.  Low risk 
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encompassed the remainder of patients.  The ART risk profiles are displayed 
in Table 4.   
 
Table 4 ART Risk Profiles 
 
 
These predictive factors were also used in the CART analysis, the results of 
which are displayed in Figure 1. 
 
 
Diagnosis 
ART Risk Profile 
Low Intermediate High 
Oropharynx Initial node size <45mm 
 Stage N2-3 disease 
 If initial weight <100kg 
o Initial node size 
>110mm 
 If initial weight >100kg 
o Initial node size 
45-55mm 
 Stage N3 disease 
 Initial weight 
>100kg 
 Initial node size 
>55mm 
Nasopharynx 
 If initial weight <100kg 
o Initial node size 
<60mm 
 If initial weight >100kg 
o Initial node size 
<15mm 
 
 Stage N2-3 disease 
 Initial weight <100kg 
 Initial node size 
>60mm 
 
 Stage N2-3 
disease 
 Initial weight 
>100kg 
 Initial node size 
>15mm 
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Figure 1 CART predicting the need to replan.  To read the CART, start at 
the first node, which represents the whole cohort, and follow the decision tree 
as appropriate for the patient to the final node in that branch.  The first line in 
each node states the probability of replan for that branch, the second line 
provides the number and percentage of patients who are categorised in that 
branch.   
 
Re-CT patient dosimetric comparison 
A significant difference was found between the median original planned dose 
and delivered dose for the GTV-n D98 (near minimum dose), GTV-n D2 (near 
maximum dose), NTT, and spinal cord maximum doses and parotid gland 
mean doses (p<0.05) (Table 5).  In all cases, the delivered dose was greater 
than the planned dose.  This increase in dose equated to ≤1% in all structures 
except the ipsilateral parotid gland (2.8%) and contralateral parotid gland 
(3.6%) with GTV-n coverage still within +/- 105% and OAR median doses less 
than the prescribed tolerance.  
 
Comparison of dosimetric impact between patients who only had a re-CT and 
those selected for replanning (prior to calculation of the replan), showed that 
replanned patients had a significantly greater ipsilateral parotid gland dose 
(p=0.02) (Table 5).  Delivered doses were also greater for the spinal cord and 
brainstem maximum dose and mean contralateral parotid gland doses, with 
the spinal cord and brainstem approaching statistical significance (p=0.06 and 
p=0.07 respectively).  When a replan was calculated for selected patients, 
OAR doses were reduced to be equivalent to the originally planned dose. 
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Table 5 Dosimetric characteristics of all re-CT patients and delivered 
median dose comparison between patients who had a re-CT 
only and those who were selected for replanning (before replan 
calculated) 
* indicates statistical significance 
GTV-n=nodal gross tumour volume, D98=dose received by 98% of structure, 
D2=dose received by 2% of structure, NTT=non target tissue 
 
 
Discussion 
Tumours in the head and neck region can undergo considerable anatomical 
changes during the course of radiotherapy, potentially leading to suboptimal 
dose distributions and overdosing of serial OAR.  This study found that NPC 
patients with more advanced nodal disease and an initial weight greater than 
100kg had the greatest likelihood of requiring a replan during treatment.  ART 
has proved to be beneficial in maintaining tumour volume coverage and 
reducing doses to surrounding OAR in the presence of anatomical change.[7, 
16, 17]  However, ART implementation involves an increased workload for 
clinical staff, including Radiation Therapists, Medical Physicists and Radiation 
Oncologists, and an increased use of departmental resources due to the 
replanning process.[18, 19]  A substantial financial burden to the department 
may also result due to the costs accompanying reimaging and replanning.  
Structure 
All re-CT patients 
Re-CT only 
(range) (Gy) 
Selected for 
replan 
(range) (Gy) 
p-
value 
Planned 
median dose 
(range) (Gy) 
Delivered 
median dose 
(range) (Gy) 
p-
value 
GTV-n D98  68.2  
(66.3-70.2) 
68.5  
(63.2-70.7) 
0.007* 68.5  
(66.4-70.7) 
67.7  
(63.2-68.5) 
0.17 
GTV-n D2  72.4  
(71-74.5) 
73.1  
(71.4-75.4) 
<0.001* 73.1  
(71-74.5) 
73  
(71.3-73.2) 
0.72 
NTT max 71.8  
(67.5-75) 
72.7  
(68.4-77.4) 
<0.001* 71.7  
(68.4-75.1) 
71.8  
(72.6-77.4) 
0.26 
Spinal cord max 43.9  
(40.6-45.7) 
44.9  
(41-46.7) 
0.05* 44.6  
(41-45.8) 
45.6  
(44.9-46.7) 
0.06 
Brainstem max 49.1  
(41.5-59.6) 
49.4  
(41.6-59.3) 
0.24 47.8  
(41.6-59.3) 
53.3  
(52-53.7) 
0.07 
Ipsilateral 
parotid gland 
mean 
42.3  
(22.9-65.8) 
43.9  
(25.3-66.6) 
<0.001* 39  
(25.3-66.1) 
63  
(60.2-66.6) 
0.02* 
Contralateral 
parotid gland 
mean 
25.6  
(19.2-40.5) 
25.7  
(19.7-41.7) 
0.001* 24.9  
(19.7-41.7) 
26.4  
(22.2-32.8) 
0.95 
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This highlights the need to identify specific factors that can predict the 
likelihood of replanning.  A proactive approach, such as the predictive models 
and risk profiles described, allows a more seamless integration of ART into 
the clinical workflow.   
 
Investigations of various external predictors for the need to replan, including 
skin separation and positional variation, did not reveal a single anatomical or 
positional variable as a reliable predictor. [20, 21]  In contrast, Capelle and 
colleagues found when assessing ART using helical Tomotherapy in HNSCC 
patients that the best predictors of patients receiving the greatest benefit were 
the degree of weight loss and reduction in neck separation.[22]  Based on 
their results, it was recommended that it would be beneficial to electively 
schedule replanning prior to the commencement of radiation therapy 
treatment for NPC patients.[22]  Similarly, the triggers used as basic 
thresholds for ART in the study by Chen et al. included dramatic weight loss, 
rapid clinical shrinkage of palpable or visible disease and/or a prolonged 
treatment break.[19]  These results are comparable to those of the current 
study where it was found that N stage, size of the pre-treatment dominant 
node, diagnosis and initial weight were significant factors in the likelihood of 
needing replanning. 
 
This study also found that NPC patients were more likely to require a replan in 
comparison to OPC patients.  This finding is similar to other studies 
investigating the role of ART in NPC patients.[7, 19, 23]  There could be 
numerous reasons explaining this finding.  Yang et al. report that anatomical 
changes such as primary tumour and/or nodal mass shrinkage and weight 
loss, are commonplace with NPC patients receiving radiotherapy.[23]  Chen 
and colleagues also comment that doses delivered to tumour volumes and 
critical OAR, such as the brainstem and optic structures, are commonly at the 
limit of the prescribed tolerance and ART can be essential in ensuring these 
OAR doses remain acceptable.[19]  In this study, potential overdosing of 
critical OAR such as the optic structures and brachial plexus were the primary 
reason for the treating Radiation Oncologist’s decision to replan.  
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Consequently, the ART risk profiles have been developed to address OPC 
and NPC patients separately. 
 
All patients who had a replan in this study had virally associated disease, 
however as a result; it was unable to be included in the predictive model.  This 
could be a reflection of the fact that more than three-quarters of patients had 
virally associated disease.  Despite this, viral status should remain a 
consideration when identifying potential patients for ART as numerous studies 
have reported the increased radioresponsiveness of virally associated OPC 
and NPC.[24-26]  
 
Logistic regression models are now more widely used in health research, 
particularly as a means to predict the risk of events.[27]  Advantages include 
ability to allow the effect of variables and their interactions on the outcome of 
interest to be estimated and the ability to estimate the strength of the 
association between the predictor and the event.[27, 28]  However, logistic 
regression results can be difficult to interpret, reducing the likelihood of its 
clinical use.  Hence, CART analysis and ART risk profiles were developed to 
facilitate ease of clinical implementation.  CART is a tree-building tool, which 
helps determine the most “important” (based on explanatory power) variables 
in a particular dataset, suited to the generation of clinical decision rules.  Both 
methods are simple to interpret and account for the inherent variations that 
exist clinically.  The results of both methods are similar and use similar 
threshold points.  The CART diagram is a much simpler approach to 
implement but does not provide the range of options that the risk profiles offer.  
The choice of approach may be dependent upon departmental preference 
and the magnitude of its HNSCC workload. 
 
In this study, only a small subset of patients was shown to benefit from ART.  
Although an overall increase was seen between the planned and delivered 
doses, this increase did not result in the GTV-n, spinal cord or brainstem 
being outside clinically acceptable tolerance levels.  The greatest amount of 
difference was seen in the delivered parotid gland dose however, for the 
parotid glands that were being spared, dose still remained clinically 
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acceptable.  This differs from the reported 20-30% of patients at a population 
level that may benefit from ART.[29]  Reasons for this may include variations 
in treatment procedures (e.g. target volume and OAR margins used) and OAR 
tolerance doses originally achieved (e.g. 61% patients achieved a mean 
contralateral parotid gland dose less than 26Gy).  However, as patient 
selection for replanning can be subjective and arbitrary, the focus of this study 
was to identify characteristics that pre-dispose patients to being more likely to 
need ART as opposed to the number of patients who actually required ART.   
 
There is variation in the literature regarding dosimetric impact of anatomic 
change on various structures.  Similar to the current study, Wu et al.[30], 
Zhang et al.[31] and Jin et al.[2] report no significant difference between 
planned and delivered doses for the GTV, spinal cord and brainstem.  They 
did observe a significant increase in parotid gland dose and recommended 
replanning in specific patients to reduce this.  Although the median delivered 
contralateral parotid gland mean dose in this study fell within clinical tolerance 
levels, 3 patients who were not replanned may have benefited from 
replanning to reduce the contralateral parotid gland mean to their originally 
planned dose. 
 
In contrast, studies conducted by Hansen et al.[6] and Zhao et al.[7] found 
that changes during treatment significantly decreased the dose to target 
volumes and significantly increased the dose to surrounding OAR such as the 
spinal cord and brainstem.  Schwartz et al. [32] found significant underdosing 
of target volumes and increases to parotid gland doses.  Although median 
doses in this study were not significantly different, considerable variability can 
be seen in the range of results obtained.  Multiple factors may contribute to 
this variability including differing time points at which plan recalculation was 
performed, relative locations of the target volumes and OAR and variable 
beam arrangements and dose gradients.  This highlights the need to 
incorporate an individualised approach when developing ART guidelines.  As 
such, the risk profiles described provide a guide for clinical decision-making.  
This may be particularly pertinent for those NPC patients whose OAR are 
commonly taken to their tolerance levels due to the proximity of high dose 
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target volumes. 
 
A limitation of this study is that there was no standard protocol in place 
governing the decision to replan.  This instead was at the discretion of the 
treating Radiation Oncologist.  Consequently, the application of these results 
must be viewed with caution due to the differences that may exist between 
Radiation Oncologists in the decision to replan.  Also, the predictive models 
and risk profiles were generated using data obtained from only a small 
number of replanned patients and this may have affected the validity of the 
results.  However, other studies support these findings with smaller numbers 
of patients reported to benefit from ART.[19, 20]  Future prospective studies, 
including the use of deformable registration tools and dose accumulation, are 
required to validate the predictive models and ART risk profiles described for 
OPC and NPC patients undergoing radiotherapy treatment.  Additionally, 
given the radiosensitivity of many head and neck cancers, the ART risk 
profiles presented are likely applicable across a wider range of HNSCC. 
 
Conclusion 
This study developed predictive models and risk profiles for clinical 
implementation to identify OPC or NPC patients that may require ART before 
treatment commencement.  This approach could facilitate effective 
implementation of ART into radiotherapy departments through forward 
planning and appropriate resource allocation. 
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